Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
FE

NASDAQ · FENC

Fennec Pharmaceuticals Inc.

Healthcare · Biotechnology

$10.24

Down-$0.71 (-6.48%)

Updated Oct 31, 2026, 12:22 PM

SID Score

5.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
206.35M
P/E ratio
-30.1
Dividend yield
0.00%
52-week range
$5.65 – $13.25
Volume
195.65K
Avg. volume
118.26K

Price performance · FENC

FENC price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

FENC closed at $10.24 after 21 trading sessions, up 0.39% for the selected period.

Last close
$10.24
Period change
+0.39%
Period low
$9.98
Period high
$10.95
Daily close
View OHLC price history
FENC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$10.89$11.05$10.14$10.24195.65K
Oct 29, 2026$10.96$11.25$10.70$10.95180.56K
Oct 28, 2026$10.62$10.89$10.39$10.87149.55K
Oct 27, 2026$10.18$10.64$10.05$10.6293.19K
Oct 26, 2026$10.08$10.27$9.98$10.15115.94K
Oct 23, 2026$10.23$10.48$9.93$10.0870.82K
Oct 22, 2026$10.33$10.51$10.12$10.32104.17K
Oct 21, 2026$10.49$10.86$10.28$10.3884.49K
Oct 20, 2026$10.12$10.73$10.12$10.4670.99K
Oct 19, 2026$10.09$10.34$9.87$10.27103.55K
Oct 16, 2026$10.20$10.35$9.87$9.98129.97K
Oct 15, 2026$9.98$10.47$9.88$10.35112.3K
Oct 14, 2026$10.10$10.31$9.92$9.98207.58K
Oct 13, 2026$10.72$10.75$10.085$10.18232.25K
Oct 12, 2026$10.68$10.83$10.4214$10.7290.13K
Oct 9, 2026$10.66$10.86$10.5698$10.7193.46K
Oct 8, 2026$10.27$10.695$10.245$10.6387.24K
Oct 7, 2026$10.21$10.66$10.0778$10.36130.79K
Oct 6, 2026$10.64$10.66$10.15$10.3599.08K
Oct 5, 2026$10.18$10.655$10.01$10.62118.02K
Oct 2, 2026$10.46$10.49$10.03$10.20136.44K

Latest FENC news

The latest Smart Investors Daily articles mentioning FENC.

Stock researchCompany · Overview

FENC research

Overview

Company profile and research snapshot.

Company profile

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$14.00
Implied upside
—
Analysts
—
FENC recent ratings
DateFirmRatingTarget
Sep 9, 2026HC Wainwright & Co.Buy—
Aug 12, 2026WedbushOutperform—
Aug 12, 2026B. Riley SecuritiesBuy—
May 22, 2026HC Wainwright & Co.Buy—
Apr 16, 2026WedbushOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 17, 2026

Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026

~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~ ~ 84% of Patients Had Grade 0 Hearing Loss by Brock Criteria; No Grade 3 or Grade 4 Hearing Loss Was Observed ~ ~ Objective Responses Observed in 23 of 24 Evaluable Patients (95.8%); Prospective Pharmacokinetic Analyses Provide New Mechanistic Insight Supporting the Six-Hour PEDMARK® Administration Interva

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By